468 related articles for article (PubMed ID: 25560838)
1. Estimates on HCV disease burden worldwide - filling the gaps.
Wedemeyer H; Dore GJ; Ward JW
J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).
Dore GJ; Ward J; Thursz M
J Viral Hepat; 2014 May; 21 Suppl 1():1-4. PubMed ID: 24713003
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
4. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
5. Predicted effects of treatment for HCV infection vary among European countries.
Deuffic-Burban S; Deltenre P; Buti M; Stroffolini T; Parkes J; Mühlberger N; Siebert U; Moreno C; Hatzakis A; Rosenberg W; Zeuzem S; Mathurin P
Gastroenterology; 2012 Oct; 143(4):974-85.e14. PubMed ID: 22863764
[TBL] [Abstract][Full Text] [Related]
6. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
Gane E; Stedman C; Brunton C; Radke S; Henderson C; Estes C; Razavi H
N Z Med J; 2014 Dec; 127(1407):61-74. PubMed ID: 25530333
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C and hepatitis B-related mortality in Spain.
García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
[TBL] [Abstract][Full Text] [Related]
8. Forecasting the disease burden of chronic hepatitis C virus in Poland.
Flisiak R; Halota W; Tomasiewicz K; Kostrzewska K; Razavi HA; Gower EE
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):70-6. PubMed ID: 25426979
[TBL] [Abstract][Full Text] [Related]
9. Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
Ueno Y; Sollano JD; Farrell GC
J Gastroenterol Hepatol; 2009 Apr; 24(4):531-6. PubMed ID: 19368633
[TBL] [Abstract][Full Text] [Related]
10. Benefits of curing hepatitis C infection.
Marinho RT; Vitor S; Velosa J
J Gastrointestin Liver Dis; 2014 Mar; 23(1):85-90. PubMed ID: 24689102
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
[TBL] [Abstract][Full Text] [Related]
12. [Hepatitis C: epidemiology natural course and diagnosis].
Moradpour D; Müllhaupt B
Rev Med Suisse; 2015 Apr; 11(471):896-901. PubMed ID: 26072594
[TBL] [Abstract][Full Text] [Related]
13. Update on hepatitis C: epidemiology, treatment and resistance to antiviral therapies.
Ness E; Kowdley KV
Minerva Gastroenterol Dietol; 2015 Sep; 61(3):145-58. PubMed ID: 25990619
[TBL] [Abstract][Full Text] [Related]
14. Disease burden of chronic hepatitis C in Brazil.
Ferreira PR; Brandão-Mello CE; Estes C; Gonçales Júnior FL; Coelho HS; Razavi H; Cheinquer H; Wolff FH; Ferraz ML; Pessoa MG; Mendes-Correa MC
Braz J Infect Dis; 2015; 19(4):363-8. PubMed ID: 26051505
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.
Aljumah AA; Abaalkhail F; Al-Ashgar H; Assiri A; Babatin M; Al Faleh F; Alghamdi A; Al-Hakeem R; Hashim A; Alqutub A; Razavi H; Sanai FM; Al-Swat K; Schmelzer J; Altraif I
Saudi J Gastroenterol; 2016; 22(4):269-81. PubMed ID: 27488321
[TBL] [Abstract][Full Text] [Related]
17. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
18. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
19. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.
Sypsa V; Touloumi G; Tassopoulos NC; Ketikoglou I; Vafiadis I; Hatzis G; Tsantoulas D; Akriviadis E; Delladetsima J; Demonakou M; Hatzakis A
J Viral Hepat; 2004 Jul; 11(4):366-74. PubMed ID: 15230860
[TBL] [Abstract][Full Text] [Related]
20. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030.
Meijerink H; White RA; Løvlie A; de Blasio BF; Dalgard O; Amundsen EJ; Melum E; Kløvstad H
BMC Infect Dis; 2017 Aug; 17(1):541. PubMed ID: 28774261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
